Sodium-dependent glucose cotransporters (SGLTs) are a family of glucose transporters that aid in the reabsorption of glucose. SGLT1 and SGLT2, which are members of the SLC5A gene family, are the two most well-known members of the SGLT family. The two transporters play a key role in maintaining glucose homeostasis by reabsorbing the filtered glucose in the kidney's tubular system (primarily SGLT2; to a lesser extent via SGLT1) and absorbing glucose from the diet in the small intestine (via SGLT1). This last process replenishes blood glucose levels and reduces urinary glucose loss. The use of SGLT1 and SGLT2 as a novel therapeutic approach for cardiomyopathy and diabetes has been suggested.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V40443 | Canagliflozin D4 | 1997338-61-0 | Canagliflozin D4 is the tetra-deuterated form of Canagliflozin(TA-7284; JNJ-24831754ZAE; JNJ 28431754-AAA; JNJ-28431754; Invokana)which is a selective SGLT2 inhibitor approved by FDA for the treatment of type 2 diabetes. |
|
V3978 | Canagliflozin hemihydrate (JNJ 28431754) | 928672-86-0 | Canagliflozin hemihydrate (alsoknown as TA-7284; JNJ-24831754ZAE; JNJ 28431754AAA; JNJ-28431754; Invokana), thehemihydrated form ofCanagliflozin,is a highly potent and selective SGLT2 inhibitor with anti-diabetic effects. |
|
V28639 | Dapagliflozin impurity | 960404-86-8 | Dapagliflozin impurity is an isomer of Dapagliflozin which is a SGLT2 (sodium-glucose transporter 2) inhibitorapproved in 2012 for thetreatment oftype 2 diabetes. |
|
V3906 | ERTUGLIFLOZIN | 1210344-57-2 | Ertugliflozin (formerly known as PF04971729; PF-04971729; trade name:Steglatro) is an orally bioactive and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2) with hypoglycemic and antidiabetic activity. |
|
V3907 | ERTUGLIFLOZIN PIDOLATE | 1210344-83-4 | Ertugliflozin pidolate(formerly known as also known as PF-04971729; trade name:Steglatro), thepidolate salt of ertugliflozin, is a potent, orally bioavailable and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2)approved in 2017 by FDA for treating type 2 diabetes mellitus. |
|
V3129 | Ipragliflozin | 761423-87-4 | Ipragliflozin (also known as ASP1941) is a novel, highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) with IC50 value of 7.4 nM for hSGLT2. |
|
V24111 | Licogliflozin (LIK-066) | 1291094-73-9 | Licogliflozin (LIK066) is a novel, potent and orally bioavailable dual inhibitor of sodium-glucose transporter-1 (SGLT1) and sodium-glucose transporter-2 (SGLT2), with an in vivo inhibitory concentration (IC50) of 22.0 nM against human SGLT1 and 0.5 nM against human SGLT2. |
|
V2785 | Tofogliflozin hydrate | 1201913-82-7 | Tofogliflozin (also known as CSG-452) hydrate is a novel, very potent and highly selective inhibitor of sodium/glucose cotransporter 2 (SGLT2) with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse respectively. |
|
V2750 | Tofogliflozin | 903565-83-3 | Tofogliflozin (also known as CSG-452) hydrate is a novel, very potent and highly selective inhibitor of sodium/glucose cotransporter 2 (SGLT2) with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
